Haleon/$HLN
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Haleon
Haleon is one of the largest consumer health companies in the world. Formed by a combination of consumer health divisions of GSK, Pfizer, and Novartis, Haleon separated from GSK and went public in July 2022. The firm generates 60% of sales from global power brands including Sensodyne, Advil, Centrum, and Poligrip, that play in many geographies and are often leaders in their respective categories. It also has a number of local brands, including Emergen-C, Eno, Tums, and Caltrate, that are more tailored to regional needs and have strong local brand equity. Overall, Haleon's brands tackle a variety of silos within consumer health including oral care, digestive health, pain relief, and nutrition.
Ticker
$HLN
Sector
Primary listing
NYSE
Employees
24,561
Headquarters
Website
Haleon Metrics
BasicAdvanced
$42B
42.43
$0.22
0.24
$0.18
1.20%
Price and volume
Market cap
$42B
Beta
0.24
52-week high
$11.42
52-week low
$8.71
Average daily volume
9.2M
Dividend rate
$0.18
Financial strength
Current ratio
0.87
Quick ratio
0.605
Long term debt to equity
48
Total debt to equity
53.413
Dividend payout ratio (TTM)
39.22%
Interest coverage (TTM)
6.38%
Profitability
EBITDA (TTM)
3,502.979
Gross margin (TTM)
63.56%
Net profit margin (TTM)
13.81%
Operating margin (TTM)
21.84%
Effective tax rate (TTM)
22.88%
Revenue per employee (TTM)
$600,280
Management effectiveness
Return on assets (TTM)
4.61%
Return on equity (TTM)
9.38%
Valuation
Price to earnings (TTM)
42.434
Price to revenue (TTM)
5.824
Price to book
2.01
Price to tangible book (TTM)
-3.4
Price to free cash flow (TTM)
29.917
Free cash flow yield (TTM)
3.34%
Free cash flow per share (TTM)
0.316
Dividend yield (TTM)
1.92%
Forward dividend yield
1.20%
Growth
Revenue change (TTM)
-2.12%
Earnings per share change (TTM)
41.64%
3-year revenue growth (CAGR)
2.75%
3-year earnings per share growth (CAGR)
2.88%
What the Analysts think about Haleon
Analyst ratings (Buy, Hold, Sell) for Haleon stock.
Haleon Financial Performance
Revenues and expenses
Haleon Earnings Performance
Company profitability
Haleon News
AllArticlesVideos
Are Haleon's headaches set to ease? Here's one leading bank's take
Proactive Investors2 weeks ago
Haleon Selects Salesforce Agentforce Life Sciences Cloud for Customer Engagement to Improve Engagement with Pharmacies and Healthcare Professionals with AI
Business Wire2 weeks ago
Haleon tops FTSE 100 fallers after downgrade
Proactive Investors1 month ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Haleon stock?
Haleon (HLN) has a market cap of $42B as of October 23, 2025.
What is the P/E ratio for Haleon stock?
The price to earnings (P/E) ratio for Haleon (HLN) stock is 42.43 as of October 23, 2025.
Does Haleon stock pay dividends?
Yes, the Haleon (HLN) stock pays dividends to shareholders. As of October 23, 2025, the dividend rate is $0.18137 and the yield is 1.2%. Haleon has a payout ratio of 39.22% on a trailing twelve-month basis.
When is the next Haleon dividend payment date?
The next Haleon (HLN) dividend payment date is unconfirmed.
What is the beta indicator for Haleon?
Haleon (HLN) has a beta rating of 0.24. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.